Tumour vasculature a potential therapeutic target

British Journal of Cancer

Volumn 72, Issue 2, 1995, Pages 257-267

  Baillie, C T ^a   Winslet, M C ^a   Bradley, N J ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Endothelium

Indexed keywords

ANGIOGENESIS; CANCER GROWTH; CANCER THERAPY; HUMAN; METASTASIS; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANIMAL; HUMAN; MOLECULAR SEQUENCE DATA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0029149810     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.323     Document Type: Article

References (153)

1. ABRAHAM JA, MERGIA A, WHANG JL, TUMOLO A, FRIEDMAN J, HJERRILD KA, GOSPODAROWICZ D AND FIDDES JC, (1986). Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science, 233, 545-548.
2. ALBO D, GRANICK MS, JHALA N, ATKINSON B AND SOLOMON MP., (1994). The relationship of angiogenesis to biological activity in human squamous cell carcinomas of the head and neck. Ann. Plastic Surg., 32, 588-594.
3. ALGIRE GH, CHALKLEY HW, LEGALLIS FY AND PARK HD., (1945). Vascular reactions of normal and malignant tissues in vivo. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J. Natl Cancer Inst., 6, 73-85.
4. ALLIEGRO MC, ALLIEGRO MA, CRAGOE EJ AND GLASER BM., (1993). Amiloride inhibition of angiogenesis in vitro. J. Exp. Zool., 267, 245-252.
5. BARRIE R, WOLTERING EA, HAJARIZADEH H, MUELLER C, URE T AND FLETCHER WS., (1993). Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J. Surg. Res., 55, 446-450.
6. BEGG AC AND TERRY NHA., (1983). Modification of stromal radiosensitivity by misonidazole and WR-2721. Br. J. Radiol., 56, 565-570.
7. BENEZRA D. (1978). Neovasculogenic ability of prostaglandins, growth factors and synthetic chemoattractants. Am. J. Opthal-mol., 86, 455-461.
8. BICKNELL R AND HARRIS AL., (1991). Novel growth regulatory factors and tumour angiogenesis. Eur. J. Cancer, 27, 781-785.
9. BICKNELL R AND HARRIS AL., (1992). Anti-cancer strategies involving the vasculature. Vascular targetting and the inhibition of angiogenesis. Semin. Cancer Biol., 3, 399-407.
10. BLEI F, WILSON L, MIGNATTI P AND RIFKIN DB., (1993). Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J. Cell Physiol., 155, 568-578.
11. BLOKSMA N, HOFHUIS F, BENAISSA-TROUW B AND WILLIERS J., (1982). Endotoxin-induced release of tumour necrosis factor and interferon in vivo is inhibited by prior adrenoceptor blockade. Cancer Immunol. Immunother., 14, 41-45.
12. BOSARI S, LEE AK, DELELLIS RA, WILEY BD, HEATLEY GJ AND SILVERMAN ML., (1992). Microvessel quantitation and prognosis in invasive breast carcinoma. Hum. Pathol., 23, 755-761.
13. BRULAND OS, FODSTAD O, STENWIG AE AND PIHL A., (1988). Expression and characteristics of a novel human osteosarcoma-associated surface antigen. Cancer Res., 48, 5302-5309.
14. BUGELSKI PJ, PORTER CW AND DOUGHERTY TJ., (1981). Autoradiographic distribution on hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res., 41, 4606-4612.
15. BURROWS FJ AND THORPE PE., (1993). Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl Acad. Sci. USA, 90, 8996-9000.
16. BURROWS FJ, WATANABE Y AND THORPE PE., (1992). A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Cancer Res., 52, 5954-5962.
17. CARMICHAEL DF, SOMMER A, THOMPSON RC, ANDERSON DC, SMITH CG, WELGUS HG AND STRICKLIN GP., (1986). Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. Proc. Natl Acad. Sci. USA, 83, 2407-2411.
18. CARSWELL EA, OLD LJ, KASSEL RL, GREEN S, FIORE N AND WILLIAMSON B., (1975). An endotoxin-induced serum factor that causes necrosis of tumours. Proc. Natl Acad. Sci. USA, 72, 3666-3670.
19. CHEIFETZ S, BELLON T, CALES C, VERA S, BERNABEU C, MASSAGUE J AND LETARTE M., (1992). Endoglin is a component of the transforming growth factor-B receptor system in human endothelial cells. J. Biol. Chem., 267, 19027-19030.
20. CHODAK GW, HAUDENSCHILD C, GITTES R AND FOLKMAN J, (1980). Angiogenic activity as a marker of neoplastic and preneoplastic lesion of the human bladder. Ann. Surg., 192. 762-771.
21. CLAPP C, MARTIAL JA, GUZMAN RC, RENTIER-DELRUE F AND WEINER RI., (1993). The 16-kilodaton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology, 133, 1292-1299.
22. CLARKE MSF AND WEST DC., (1991). The identification of proliferation and tumour-induced proteins in human endothelial cells: A possible target for tumour therapy. Electrophoresis, 12, 500-508.
23. CLAUSS M, MURRAY JC, VIANNA M, DE WAAL R, THURSTON G, NAWROTH P, GERLACH H, BACH R, FAMILLETTI PC AND STERN D., (1990). A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J. Biol. Chem., 265, 7078-7083.
24. DANESI R, DEL BIANCHI S, SOLDANI P, CAMPAGNI A, LA ROCCA RV, MYERS CE, PAPARELLI A AND DEL TACCA M., (1993). Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br. J. Cancer, 68, 932-938.
25. DENEKAMP J. (1982). Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br. J. Cancer, 45, 136-139.
26. DENEKAMP J. (1990). Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev., 9, 267-282.
27. DENEKAMP J. (1993). Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol, 66, 181-196.
28. DENEKAMP J AND HOBSON B., (1982). Endothelial cell proliferation in experimental tumours. Br. J. Cancer, 46, 711-720.
29. DERYNCK R, JARRETT JA, CHEN EY, EATON DH, BELL JR, ASSOIAN RK, ROBERTS AB, SPORN MB AND GOEDDEL DV., (1985). Human transforming growth factor-ß complementary DNA sequence and expression in normal and transformed cells. Nature, 316, 701-705.
30. DVORAK HF AND GRESSER I., (1989). Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J. Natl Cancer Inst., 81, 497-502.
31. DVORAK HF, NAGY JA, DVORAK JT AND DVORAK AM., (1988). Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133, 95-109.
32. DVORAK HF, NAGY JA AND DVORAK AM., (1991). Structure of solid tumours and their vasculature: Implications for therapy with monoclonal antibodies. Cancer Cells, 3, 77-85.
33. ENDRICH B, ZWEIFACH BW, REINHOLD HS AND INTAGLIETTA M., (1979). Quantitative studies of microcirculatory function in malignant tissue: Influence of temperature on microvascular haemodynamics during the early growth of the BA1112 rat sarcoma. Int. J. Radiat. Oncol. Biol. Phys., 5, 2021-2030.
34. ESCH F, UENO N, BAIRD A, HILL F, DENOROY L, LING N, GOS-PODAROWICZ D AND GUILLEMIN R., (1985a). Primary structure of bovine brain acidic fibroblast growth factor (FGF). Biochem. Biophys. Res. Commun., 133, 554-562.
35. ESCH F, BAIRD A, LING N, UENO N, HILL F, DENOROY L, KLEPPER R, GOSPODAROWICZ D, BOHLEN P AND GUILLEMIN R., (1985b). Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc. Natl Acad. Sei. USA, 82, 6507-6511.
36. FAJARDO LF, SCHREIBER AB, KELLY NI AND HAHN GM., (1985). Thermal sensitivity of endothelial cells. Radiat. Res., 103, 276-285.
37. FAN TD, HU D, GUARD S, GRESHAM GA AND WATLING KJ., (1993). Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK, or interleukin-1 receptor antagonists. Br. J. Pharmacol., 110, 43-49.
38. FANG W, HARTMANN N, CHOW DT, RIEGEL AT AND WELLSTEIN A., (1992). Pleitrophin stimulates fibroblasts and endothelial cells and epithelial cells and is expressed in human cancer. J. Biol. Chem., 267, 25889-25897.
39. FERNANDEZ LA, TWICKLER J AND MEAD A., (1985). Neovascularization produced by angiotensin II. J. Lab. Clin. Med., 105, 141-145.
40. FETT JW, STRYDOM DJ, LOBB RR, ALDERMAN EM, BETHUNE JL, RIORDAN JF AND VALLEE BL., (1985). Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry, 24, 5480-5486.
41. FINNIS C, DODSWORTH N, POLLITT CE, CARR G AND SLEEP D., (1993). Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity. Eur. Jo. Biochem., 212, 201-210.
42. FOLKMAN J. (1972). Anti-angiogenesis: New concept for therapy of solid tumors. Ann. Surg., 175, 409-416.
43. FOLKMAN J. (1984). Angiogenesis. In Biology of Endothelial Cells, Jaffe EA. (ed.) pp. 412-428. Martinus Nijhoff: The Hague.
44. FOLKMAN J. (1985) Tumour angiogenesis. Adv. Cancer Res., 43, 175-203.
45. FOLKMAN J AND INGBER DE., (1987). Angiostatic steroids. Ann. Surg., 206, 374-383.
46. FOLKMAN J, MERLER E, ABERNATHY C AND WILLIAMS G., (1971). Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med., 133, 275-288.
47. FOLKMAN J, WEISZ PB, JOULLIE MM, LI WW AND EWING WR., (1989). Control of angiogenesis with synthetic heparin substitutes. Science, 243, 1490-1493.
48. 2and angiogenesis. Proc. Soc. Exp. Biol. Med., 172, 214-218.
49. FOX SB, GATTER KC, BICKNELL R, GOING JJ, STANTON P, COOKE TG AND HARRIS AL., (1993). Relationship of endothelial cell proliferation to tumour vascularity in human breast cancer. Cancer Res., 53, 4161-4163.
50. FRATER-SCHRODER M, RISAU W, HALLMANN R, GAUTSCHI P AND BOHLEN P., (1987). Tumor necrosis factor type a, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Natl Acad. Sei. USA, 84, 5277-5281.
51. FREGENE TA, KHANUJA PS, NOTO AC, GEHANI SK, VAN EGMONT EM, LUZ DA AND PIENTA KJ., (1993). Tumor-associated angiogenesis in prostatic cancer. Anticancer Res., 13, 2377-2381.
52. FREUDENBERG N, RIESE KH AND FREUDENBERG MA., (1983). The vascular endothelial system. Veroff Pathol., 120, 1 – 114.
53. FURUKAWA T, YOSHIMURA A, SUMIZAWA T, HARAGUCHI M AND AKIYAMA S., (1992). Angiogenic factor. Nature, 356, 668.
54. GIMBRONE MA, COTRAN RS, LEAPMAN SB AND FOLKMAN J., (1974). Tumor growth and neovascularization: An experimental model using the rabbit cornea. J. Natl Cancer Inst., 52, 413-427.
55. GIMBRONE MA, LEAPMAN SB, COTRAN RS AND FOLKMAN J., (1972). Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med., 136, 261-276.
56. GOOD DJ, POLVERINI PJ, RASTINEJAD F, LE BEAU MM, LEMONS RS, FRAZIER WA AND BOUCK NP., (1990). A tumor supressor-dependent inhibitor Of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl Acad. Sei. USA, 87, 6624-6628.
57. GOUGOS A AND LETARTE M., (1990). Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J. Biol. Chem., 265, 8361-8364.
58. GRANT DS, TASHIRO K, SEGUI-REAL B, YAMADA Y, MARTIN GR AND KLEINMAN HK., (1989). Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell, 58, 933-943.
59. GROSS JL, HERBLIN WF, DUSAK BA, CZERNIAK P, DIAMOND M AND DEXTER DL., (1990). Modulation of solid tumor growth in vivo by bFGF (abstract). Proc. Am. Assoc. Cancer Res., 31, 79.
60. GUNDUZ N. (1981). Cytokinetics of tumour and endothelial cells and vascularization of lung metastases in C3H/He mice. Cell Tissue Kinetics, 14, 343-363.
61. HAGEMEIER H, VOLLMER E, GOERDT S, SCHULZE-OSTHOFF K AND SORG C., (1986). A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with normal adult tissues. Int. J. Cancer, 38, 481-488.
62. HART MN, DEBAULT LE, SADEWASSER KL, CANCILLA PA AND HENRIQUEZ EM., (1981). Morphological effects of antibody to mouse brain endothelium in vivo. J. Neuropathol. Exp. Neurol., 40, 84-91.
63. HERTIG AT. (1935). Angiogenesis in the early human chorion and in the primary placenta of the Macaque monkey. Contrib. Embryol., 25, 37-81.
64. HILLS S, WILLIAMS KB AND DENEKAMP J., (1989). Vascular collapse after flavone acetic acid: A possible mechanism for its anti-tumour action. Eur. J. Cancer Clinical Oncol., 25, 1419-1424.
65. HIRST DG, DENEKAMP J AND HOBSON B., (1982). Proliferation kinetics of endothelial and tumour cells in three mouse mammary carcinomas. Cell Tissue Kinetics, 15, 251-261.
66. HORAK ER, LEEK R, DELELLIS RA, WILEY BC, HEATLEY GJ AND SILVERMAN ML., (1992). Quantitative angiogenesis assessed by anti-PECAM (platelet/endothelial cell adhesion molecule) antibodies: Correlation with node metastases and survival in breast cancer. Lancet, 340, 1120-1124.
67. HORI A, SASADA R, MATSUTANI E, NAITO K, SAKURA Y, FUJITA T AND KOZAI Y., (1991). Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res., 51, 6180-6184.
68. HORI K, SUZUKI M, TANDA S AND SAITO S., (1990). In vivo analysis of tumor vascularization in the rat. Jpn J. Cancer Res., 81, 279-288.
69. IDE AG, BAKER NH AND WARREN SL., (1939). Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am. J. Roentgenol., 42, 891-899.
70. INGBER D. (1991). Extracellular matrix and cell shape: Potential control points for inhibition of angiogenesis. J. Cell Biochem., 47, 236-241.
71. INGBER DE AND FOLKMAN J., (1989). How does extracellular matrix control capillary morphogenesis? Cell, 58, 803-805.
72. INGBER D, FUJITA T, KISHIMOTO S, SUDO K, KANAMARU T, BREM H AND FOLKMAN J., (1990). Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature, 348, 555-557.
73. ISHIKAWA F, MIYAZONO K, HELLMAN U, DREXLER H, WERN-STEDT C, HAGIWARA K, USUKI K, TAKAKU F, RISAU W AND HELDIN C-H., (1989). Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature, 338, 557-561.
74. KALLINOWSKI F, SCHAEFER C, TYLER G AND VAUPEL P., (1989). In vivo targets of recombinant tumour necrosis factor-a: Blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br. J. Cancer, 60, 555-560.
75. KAO J, RYAN J, BRETT G, CHEN J, SHEN H, FAN YG, GODMAN G, FAMILLETTI PC, WANG F, PAN YC, STERN D AND CLAUSS M., (1992). Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-responsexmechanisms. J. Biol. Chem., 267, 20239-20247.
76. KECK PJ, HAUSER SD, KRIVI G, SANZO K, WARREN T, FEDER J AND CONNOLLY DT., (1989). Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science, 246, 1309-1311.
77. KIM KJ, LI B, WINER J, ARMANINI M, GILLETT N, PHILLIPS HS AND FERRARA N., (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841-844.
78. KLAGSBRUN M AND D’AMORE PA., (1991). Regulators of angiogenesis. Annu. Rev. Physiol., 53, 217-239.
79. KNIGHTON D, AUSPRUNK D, TAPPER D AND FOLKMAN J., (1977). Avascular and vascular phases of tumour growth in the chick embryo. Br. J. Cancer, 35, 347-356.
80. KONDO S, ASANO M AND SUZUKI H., (1993). Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem. Biophys. Res. Commun., 194, 1234-1241.
81. KOTASEK D, VERCELLOTTI GM, OCHOA AC, BACH FH, WHITE JG AND JACOB HS., (1988). Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells. Cancer Res., 48, 5528-5532.
82. KULL JR FC, BRENT DA, PARIKH I AND CUATRECASAS P., (1987). Chemical identification of a tumor-derived angiogenic factor. Science, 236, 843-845.
83. KURACHI K, DAVIE EW, STRYDOM DJ, RIORDAN JF AND VALLEE BL., (1985). Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor. Biochemistry, 24, 5494-5499.
84. LASTRES P, BELLON T, CABANAS C, SANCHEZ-MADRID F, ACEVEDO A, GOUGOS A, LETARTE M AND BERNABEU C., (1992). Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur. J. Immunol., 22, 393-397.
85. LAZO JS. (1986). Endothelial injury caused by antineoplastic agents. Biochem. Pharmacol., 35, 1919-1923.
86. LEIBOVICH SJ, POLVERINI PJ, SHEPARD HM, WISEMAN DM, SHIVELY V AND NUSEIR N., (1987). Macrophage-induced angiogenesis is mediated by tumour necrosis factor-a. Nature, 329, 630-632.
87. LEONE A, FLATOW U, KING CR, SANDEEN MA, MARGULIES IM, LIOTTA LA AND STEEG PS., (1991). Reduced tumor incidence, metastatic potential and cytokine responsiveness of nm23-transfected melanoma cells. Cell, 65, 25-35.
88. LEUNG DW, CACHIANES G, KUANG W, GOEDDEL DV AND FERRARA N., (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246, 1306-1309.
89. LIEN WM AND ACKERMAN NB. (1970). The blood supply of experimental liver metastases. II. A microcirculatory study of normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery, 68, 334-340.
90. LIOTTA LA, STEEG PS AND STETLER-STEVENSON WG. (1991). Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell, 64, 337-350.
91. McAUSLAN BR AND HOFFMAN H. (1979). Endothelium stimulating factor from Walker carcinoma cells. Exp. Cell Res., 119, 181-190.
92. MAIONE TE, GRAY GS, PETRO J, HUNT AJ, DONNER AL, BAUER SI, CARSON HF AND SHARPE RJ. (1990). Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science, 247, 77-79.
93. MARQUARDT H, HUNKAPILLER MW, HOOD LE AND TODARO GJ., (1984). Rat transforming growth factor type 1: Structure and relation to epidermal growth factor. Science, 233, 1079-1082.
94. MATSUBARA T, SAURA R, HIROHATA K AND ZIFF M., (1989). Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J. Clin. Invest., 83, 158-167.
95. MATSUZAKI K, YOSHITAKE Y, MATUO Y, SASAKI H AND NISHIKAWA K., (1989). Monoclonal antibodies against heparin-binding growth factor ll/basic fibroblast growth factor that block its biological activity: Invalidity of the antibodies for tumor angiogenesis. Proc. Natl Acad. Sci. USA, 86, 9911-9915.
96. MATTSSON J, APPELGREN L, HAMBERGER B AND PETERSON H., (1979). Tumor vessel innervation and influence of vasoactive drugs on tumor blood flow. In Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors, Peterson H. (ed.) pp. 129-135. CRC Press: Boca Raton, FL.
97. MILLAUER B, SHAWVER LK, PLATE KH, RISAU W AND ULLRICH A., (1994). Glioblastoma growth inhibited in vivo by a dominantnegative Flk-1 mutant. Nature, 367, 576-579.
98. MOGHADDAM A AND BICKNELL R., (1992). Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry, 31, 12141-12146.
99. MORRIS PB, ELLIS MN AND SWAIN JL., (1989). Angiogenic potency of nucleotide metabolites: Potential role in ischaemia-induced vascular growth. J. Mol. Cell Cardiol., 21, 351-358.
100. MOSES MA, SUDHALTER J AND LANGER R., (1990). Identification of an inhibitor of neovascularization from cartilage. Science, 248, 1408-1410.
101. MOTRO B, ITIN A, SACHS L AND KESHET E., (1990). Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc. Natl Acad. Sci. USA, 87, 3092-3096.
102. MULLER WA, RATTI CM, McDONNELL SL AND COHN ZA., (1989). A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions. J. Exp. Med., 170, 399-340.
103. MURATA J, SAIKI I, MAKABE T, TSUTA Y, TOKURA S AND AZUMA I., (1991). Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives. Cancer Res., 51, 22-26.
104. MURRAY JC, RANDHAWA VS AND DENEKAMP J., (1987). The effects of melphalan and misonidazole on the vasculature of murine sarcoma. Br. J. Cancer, 55, 233-238.
105. MURRAY JC, SMITH KA AND LAUK S., (1989). Vascular markers for murine tumours. Radiother. Oncol., 16, 221-234.
106. ODEDRA R AND WEISS JB., (1991). Low molecular weight angiogenesis factors. Pharmacol. Ther., 49, 111-124.
107. OHTSU A, FUJII K AND KUROZUMI S., (1988). Induction of angiogenic response by chemically stable prostacyclin analogs. Prostaglandins Leukotines Essential Fatty Acids, 33, 35-39.
108. OIKAWA T, HIROTANI K, SHIMAMURA M, ASHINO-FUSE H AND IWAGUCHI T., (1989). Powerful antiangiogenic activity of her-bimycin A (named angiostatic antibiotic). J. Antibiot., 42, 1202-1204.
109. 3analogues. Eur. J. Pharmacol., 178, 247-250.
110. OIKAWA T, SHIMAMURA M, ASHINOFUSE H, IWAGUCHI T, ISHIZUKA M AND TAKEUCHI T. (1991). Inhibition of angiogenesis by 15-deoxyspergualin. J. Antibiot., 44, 1033-1035.
111. OOSTERWIJK E, RUITER DJ, WAKKA JC, HUISKENS-VAN DER MEIJ JW, JONAS U, FLEUREN GJ, ZWARTENDIJK J, HOEDEMAEKER P AND WARNAAR SO., (1986). Immunohis-tochemical analysis of monoclonal antibodies to renal antigens: Application in the diagnosis of renal cell carcinoma. Am. J. Pathol., 123, 301-309.
112. ORCHARD PJ, SMITH CM, WOODS WG, DAY DL, DEHNER LP AND SHAPIRO R., (1989). Treatment of haemangioendotheliomas with alpha interferon. Lancet, 8662, 565-567.
113. PHILLIPS P AND KUMAR S., (1979). Tumour angiogenesis factor (TAF) and its neutralization by a xenogenic antiserum. Int. J. Cancer, 23, 82-88.
114. PLATE KH, BREIER G, WEICH HA AND RISAU W., (1992). Vascular endothelial growth factor is a potent tumour angiogenesis factor in human gliomas in vivo. Nature, 359, 845-848.
115. RASTINEJAD F, POLVERINI PJ AND BOUCK NP., (1989). Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell, 56, 345-355.
116. REILLY TM, TAYLOR DS, HERBLIN WF, THOOLEN MJ, CHIU AT, WATSON DW AND TIMMERMANS PB., (1989). Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivo. Biochem. Biophys. Res. Commun., 164, 736-743.
117. REINHOLDS HS, BLACHIWIECZ B AND VAN DEN BERGBLOK AE., (1978). Cancer Therapy by Hyperthermia and Radiation. Urban and Schwarzenberg: Baltimore.
118. RETTIG WJ, GARIN-CHESA P, HEALEY JH, SU SL, JAFFE EA AND OLD LJ., (1992). Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc. Natl Acad. Sci. USA, 89, 10832-10836.
119. RISAU W, DREXLER H, MIRONOV V, SMITS A, SIEGBAHN A, FUNA K AND HELDIN CH., (1992). Platelet-derived growth factor is angiogenic in vivo. Growth Factors, 7, 261-266.
120. ROBERTS AB, SPORN MB, ASSOIAN RK, SMITH JM, ROCHE NS, WAKEFIELD LM, HEINE UI, LIOTTA LA, FALANGA V, KEHRL JH AND FAUCI AS., (1986). Transforming growth factor type ß: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl Acad. Sci. USA, 83, 4167-4171.
121. ROSENGARD AM, KRUTZSCH HC, SHEARN A, BIGGS JR, BARKER E, MARGULIES IM, KING CR, LIOTTA LA AND STEEG PS., (1989). Reduced nm23/awd protein in tumour metastasis and aberrant Drosophila development. Nature, 342, 177-180.
122. SCHREIBER AB, WINKLER ME AND DERYNCK R., (1986). Transforming growth factor-a: A more potent angiogenic mediator than epidermal growth factor. Science, 232, 1250-1253.
123. SCHULTZ-HECTOR S AND HAGHAYEGH S., (1993). ß-Fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial proliferation. Cancer Res., 53, 1444-1449.
124. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res., 50, 1774-1778.
125. SHAPIRO R AND VALLEE BL., (1987). Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. Proc. Natl Acad. Sci. USA, 84, 2238-2241.
126. SHWEIKI D, ITIN A, SOFFER D AND KESHET E., (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359, 843-845.
127. SIDKY YA AND BORDEN EC., (1987). Inhibition of angiogenesis by interferons: Effects on tumor-and lymphocyte-induced vascular responses. Cancer Res., 47, 5155-5161.
128. SOLESVIK OV, ROFSTAD EK AND BRUSTAD T., (1984). Vascular changes in a human malignant melanoma xenograft following single-dose irradiation. Radiat Res., 98, 115-128.
129. SRIVASTAVA A, LAIDLER P, DAVIES RP, MORGAN K AND HUGHES LE., (1988). The prognostic significance of tumor vascularity in intermediate-thickness (0.74-4.0 mm thick) skin melanoma. Am. J. Pathol., 133, 419-423.
130. STAR WM, MARIJNISSEN HPA, VAN DEN BERG-BLOK AE, VERS-TEEG JAC, FRANKEN KAP AND REINHOLD HS., (1986). Destruction of rat mammary tumor and abnormal tissue microcirculation by haematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res., 46, 2531-2540.
131. STETLER-STEVENSON WG, KRUTZSCH HC AND LIOTTA LA., (1989). Tissue inhibitor of metalloproteinase (TIMP-2). J. Biol. Chem., 264, 17374-17378.
132. TAMARGO RJ, BOK RA AND BREM H., (1991). Angiogenesis inhibition by minocycline. Cancer Res., 51, 672-675.
133. TANNOCK IF., (1970). Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res., 30, 2470-2476.
134. TAYLOR S AND FOLKMAN J., (1982). Protamine is an inhibitor of angiogenesis. Nature, 297, 307-312.
135. THOMLINSON RH AND GRAY LH., (1965). The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer, 9, 539-549.
136. THORPE PE, DERBYSHIRE EJ, KING SW AND BURROWS FJ., (1994). Targeting the vasculature of carcinomas and other solid tumors (abstract). Am. Assoc. Cancer Res. 35, 379.
137. USUKI K, SARAS J, WALTENBERGER J, MIYAZONO K, PIERCE G, THOMASON A AND HELDIN CH., (1992). Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem. Biophys. Res. Commun., 184, 1311-1316.
138. VAUPEL P, KALLINOWSKI F AND OKUNIEFF P., (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res., 49, 6449-6465.
139. VUKANOVIC J, PASSANITI A, HIRATA T, TRAYSTMAN RJ, HARTLEY-ASP B AND ISAACS JT., (1993). Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res., 53, 1833-1837.
140. WAKAMATSU K, MASAKI T, ITOH F, KONDO K AND SUDO K.,(1990). Isolation of a fatty acid amide as an angiogenic principle from bovine mesentery. Biochem. Biophys. Res. Commun., 168, 423-429.
141. WANG JM, KUMAR S, PYE D, VAN AGTHOVEN AJ, KRUPINSKI J AND HUNTER RD., (1993). A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues (abstract). Int. J. Cancer, 54, 363-370.
142. WARD WF, SOLLIDAY NH, MOLTENI A AND PORT CD., (1983). Radiation injury in rat lung II. Angiotensin-converting enzyme activity. Radiat Res., 96, 294-300.
143. WARREN BA. (1979). The vascular morphology of tumors. In Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors, Peterson H. (ed.) pp. 1-47. CRC Press: Boca Raton, FL.
144. WEIDNER N., (1993). Tumor angiogenesis: Review of current applications in tumor prognostication. Semin. Diagnostic Pathol., 10, 302-313.
145. WEIDNER N, SEMPLE JP, WELCH WR AND FOLKMAN J., (1991). Tumor angiogenesis and metastasis -correlation in invasive breast carcinoma. N. Engl. J. Med., 32, 1-8.
146. WEIDNER N, FOLKMAN J, POZZA F, BEVILACQUA P, ALLRED EN, MOORE DH, MELI S AND GASPARINI G., (1992). Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl Cancer Inst., 84, 1875-1887.
147. WEISS JB, BROWN RA, KUMAR S AND PHILLIPS P., (1979). An angiogenic factor isolated from tumours: A potent low-molecular-weight compound. Br. J. Cancer, 40, 493-496.
148. WEISS RB, GREENE RF, KNIGHT RD, COLLINS JM, PELOSI JJ, SULKES A AND CURT GA., (1988). Phase 1 and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512). Cancer Res., 48, 5878-5882.
149. WEST CML, WEST DC AND KUMAR S., (1990). A comparison of the sensitivity to photodynamic treatment of endothelial and tumour cells in different proliferative states. Int. J. Radiat. Biol., 58, 145-156.
150. YATES RA, NANNEY LB, GATES RE AND KING JR LE., (1991). Epidermal growth factor and related growth factors. Int. J. Dermatol., 30, 687-694.
151. ZICHE M AND GULLINO PM., (1982). Angiogenesis and neoplastic progression in vitro. J. Natl Cancer Inst., 69, 483-487.
152. ZICHE M, MORBIDELLI L, PACINI M, GEPPETTI P, ALESSANDRI G AND MAGGI CA., (1990). Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Mic-rovasc. Res., 40, 264-278.
153. ZWI U, BAGULEY BC, GAVIN JB AND WILSON WR., (1990). The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels. Br. J. Cancer, 62, 231-237.